Prostatic intraepithelial neoplasia: An update

Liang Cheng, Ryan F. Paterson, Stephen D W Beck, Jodi Parks

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

High-grade prostatic intraepithelial neoplasia (HGPIN) is commonly encountered on prostate needle biopsies and, based on epidemiologic, molecular, and animal models, has proven to be the most significant risk factor for prostate cancer and likely represents the premalignant phase of prostatic adenocarcinoma. This lesion is characterized by cellular proliferations within pre-existing ducts and glands, with nuclear and nucleolar enlargement similar to prostate cancer. However, unlike cancer, HGPIN retains a basal cell layer identifiable by immunohistochemistry with the basal cell-specific antibody cytokeratin 34βE12. The incidence of HGPIN identified in needle biopsies is as high as 25%, increases with age, and coexists with prostate cancer in approximately 85% of cases. There appears to be no causal relationship between HGPIN and serum prostate-specific antigen (total, percent free, or density) or radiographic characteristics on transrectal ultrasound. In a large series, the identification of HGPIN on initial needle biopsy is associated with about a 35% risk of prostate cancer on subsequent biopsies. Thus, the finding of HGPIN on prostate needle biopsy necessitates a second biopsy in a patient eligible for curative treatment. As a precursor lesion, HGPIN is currently a target for chemopreventive strategies, including antiandrogens and nutritional supplementation.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalClinical Prostate Cancer
Volume3
Issue number1
StatePublished - Jun 2004

Fingerprint

Prostatic Intraepithelial Neoplasia
Needle Biopsy
Prostatic Neoplasms
Prostate
Biopsy
Androgen Antagonists
Molecular Models
Prostate-Specific Antigen
Keratins
Adenocarcinoma
Animal Models
Immunohistochemistry
Cell Proliferation
Antibodies
Incidence
Serum

Keywords

  • Adenocarcinoma
  • Chemoprevention
  • Needle biopsy
  • Prognosis
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Cheng, L., Paterson, R. F., Beck, S. D. W., & Parks, J. (2004). Prostatic intraepithelial neoplasia: An update. Clinical Prostate Cancer, 3(1), 26-30.

Prostatic intraepithelial neoplasia : An update. / Cheng, Liang; Paterson, Ryan F.; Beck, Stephen D W; Parks, Jodi.

In: Clinical Prostate Cancer, Vol. 3, No. 1, 06.2004, p. 26-30.

Research output: Contribution to journalArticle

Cheng, L, Paterson, RF, Beck, SDW & Parks, J 2004, 'Prostatic intraepithelial neoplasia: An update', Clinical Prostate Cancer, vol. 3, no. 1, pp. 26-30.
Cheng L, Paterson RF, Beck SDW, Parks J. Prostatic intraepithelial neoplasia: An update. Clinical Prostate Cancer. 2004 Jun;3(1):26-30.
Cheng, Liang ; Paterson, Ryan F. ; Beck, Stephen D W ; Parks, Jodi. / Prostatic intraepithelial neoplasia : An update. In: Clinical Prostate Cancer. 2004 ; Vol. 3, No. 1. pp. 26-30.
@article{973dae1ac42d4945ad7914b1b0c35bf9,
title = "Prostatic intraepithelial neoplasia: An update",
abstract = "High-grade prostatic intraepithelial neoplasia (HGPIN) is commonly encountered on prostate needle biopsies and, based on epidemiologic, molecular, and animal models, has proven to be the most significant risk factor for prostate cancer and likely represents the premalignant phase of prostatic adenocarcinoma. This lesion is characterized by cellular proliferations within pre-existing ducts and glands, with nuclear and nucleolar enlargement similar to prostate cancer. However, unlike cancer, HGPIN retains a basal cell layer identifiable by immunohistochemistry with the basal cell-specific antibody cytokeratin 34βE12. The incidence of HGPIN identified in needle biopsies is as high as 25{\%}, increases with age, and coexists with prostate cancer in approximately 85{\%} of cases. There appears to be no causal relationship between HGPIN and serum prostate-specific antigen (total, percent free, or density) or radiographic characteristics on transrectal ultrasound. In a large series, the identification of HGPIN on initial needle biopsy is associated with about a 35{\%} risk of prostate cancer on subsequent biopsies. Thus, the finding of HGPIN on prostate needle biopsy necessitates a second biopsy in a patient eligible for curative treatment. As a precursor lesion, HGPIN is currently a target for chemopreventive strategies, including antiandrogens and nutritional supplementation.",
keywords = "Adenocarcinoma, Chemoprevention, Needle biopsy, Prognosis, Prostate-specific antigen",
author = "Liang Cheng and Paterson, {Ryan F.} and Beck, {Stephen D W} and Jodi Parks",
year = "2004",
month = "6",
language = "English",
volume = "3",
pages = "26--30",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Prostatic intraepithelial neoplasia

T2 - An update

AU - Cheng, Liang

AU - Paterson, Ryan F.

AU - Beck, Stephen D W

AU - Parks, Jodi

PY - 2004/6

Y1 - 2004/6

N2 - High-grade prostatic intraepithelial neoplasia (HGPIN) is commonly encountered on prostate needle biopsies and, based on epidemiologic, molecular, and animal models, has proven to be the most significant risk factor for prostate cancer and likely represents the premalignant phase of prostatic adenocarcinoma. This lesion is characterized by cellular proliferations within pre-existing ducts and glands, with nuclear and nucleolar enlargement similar to prostate cancer. However, unlike cancer, HGPIN retains a basal cell layer identifiable by immunohistochemistry with the basal cell-specific antibody cytokeratin 34βE12. The incidence of HGPIN identified in needle biopsies is as high as 25%, increases with age, and coexists with prostate cancer in approximately 85% of cases. There appears to be no causal relationship between HGPIN and serum prostate-specific antigen (total, percent free, or density) or radiographic characteristics on transrectal ultrasound. In a large series, the identification of HGPIN on initial needle biopsy is associated with about a 35% risk of prostate cancer on subsequent biopsies. Thus, the finding of HGPIN on prostate needle biopsy necessitates a second biopsy in a patient eligible for curative treatment. As a precursor lesion, HGPIN is currently a target for chemopreventive strategies, including antiandrogens and nutritional supplementation.

AB - High-grade prostatic intraepithelial neoplasia (HGPIN) is commonly encountered on prostate needle biopsies and, based on epidemiologic, molecular, and animal models, has proven to be the most significant risk factor for prostate cancer and likely represents the premalignant phase of prostatic adenocarcinoma. This lesion is characterized by cellular proliferations within pre-existing ducts and glands, with nuclear and nucleolar enlargement similar to prostate cancer. However, unlike cancer, HGPIN retains a basal cell layer identifiable by immunohistochemistry with the basal cell-specific antibody cytokeratin 34βE12. The incidence of HGPIN identified in needle biopsies is as high as 25%, increases with age, and coexists with prostate cancer in approximately 85% of cases. There appears to be no causal relationship between HGPIN and serum prostate-specific antigen (total, percent free, or density) or radiographic characteristics on transrectal ultrasound. In a large series, the identification of HGPIN on initial needle biopsy is associated with about a 35% risk of prostate cancer on subsequent biopsies. Thus, the finding of HGPIN on prostate needle biopsy necessitates a second biopsy in a patient eligible for curative treatment. As a precursor lesion, HGPIN is currently a target for chemopreventive strategies, including antiandrogens and nutritional supplementation.

KW - Adenocarcinoma

KW - Chemoprevention

KW - Needle biopsy

KW - Prognosis

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=3442884218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442884218&partnerID=8YFLogxK

M3 - Article

C2 - 15279687

AN - SCOPUS:3442884218

VL - 3

SP - 26

EP - 30

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -